XML 131 R114.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Product Information [Line Items] |  |  |  |
Revenues |  | $ 15,846 | $ 14,925 | $ 15,878
North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 8,124 | 7,452 | 7,809
Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 4,837 | 4,525 | 4,886
International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,958 | 1,903 | 2,032
Generic products [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 3,475 | 3,549 | 3,769
Generic products [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 3,664 | 3,466 | 3,569
Generic products [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,594 | 1,586 | 1,649
AJOVY [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 230 | 218 | 176
AJOVY [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 160 | 124 | 87
AJOVY [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 44 | 35 | 50
AUSTEDO [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,225 | 963 | 802
BENDEKA and TREANDA [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 241 | 316 | 385
COPAXONE [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 320 | 387 | 577
COPAXONE [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 231 | 268 | 391
COPAXONE [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 39 | 36 | 37
Anda [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,577 | 1,471 | 1,323
Respiratory Product [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 265 | 273 | 356
Other [Member] | North America [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues | [1] | 1,056 | 549 | 777
Other [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues | [2] | 516 | 393 | 483
Other [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | $ 281 | $ 246 | $ 295
[1] | Other revenues were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.
[2] | Other revenues in 2023 were mainly related to the sale of certain product rights.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericsMediciansMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AjovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_COPAXONEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_RespiratoryProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |